Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology-Oncology, Medicine, Duke University 2005 - 2007
  • Fellow in Hematology-Oncology, Medicine, Duke University 2003 - 2004
  • Resident in Medicine, Medicine, Duke University 2000 - 2003
  • M.D., Thomas Jefferson University 2000
• 

  Duke Appointment History

  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2013 - 2017
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2007 - 2013
  • Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2007
  • Associate in the Department of Medicine, Medicine, General Internal Medicine, Medicine 2004 - 2005
• Recognition
• 

  In the News

  • MAR 4, 2015

    Australian Broadcasting’s “Health Report”

    Dr. Richard Riedel: Early palliative care can cut hospital re-admissions for cancer patients

  • NOV 7, 2014

    Duke Chronicle

    Duke revolutionizes cancer care, garners national attention

  • OCT 22, 2014

    Early Palliative Care Can Cut Hospital Readmissions for Cancer Patients
• Research
• 

  Selected Grants

  • IMDZ-04-1702 awarded by Immune Design Corp. 2018 - 2023
  • TK216-01 awarded by Oncternal Therapeutics, Inc. 2018 - 2023
  • NC-6300-001_Nanoparticle Epirubicin awarded by NanoCarrier Co., Ltd. 2017 - 2022
  • STARTRK-2 awarded by Ignyta 2017 - 2022
  • SARC032 awarded by Sarcoma Alliance for Research Through Collaboration 2017 - 2022
  • KCP-330-020 awarded by Karyopharm Therapeutics 2016 - 2021
  • IMDZ-C232 awarded by Immune Design Corp. 2016 - 2021
  • A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewin awarded by Sarcoma Alliance for Research Through Collaboration 2014 - 2020
  • Lilly JGDJ awarded by Eli Lilly and Company 2015 - 2020
  • PEComa awarded by AADi LLC 2015 - 2020
  • PLX108-10 awarded by Daiichi Pharmaceutical Corporation 2015 - 2020
  • SARC 028 awarded by Sarcoma Alliance for Research Through Collaboration 2015 - 2020
  • A Phase IB Dose-Escalation Study of TRC105 in combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma awarded by Tracon Pharmaceuticals, Inc. 2013 - 2019
  • ARO-012 (CrenoGIST) awarded by Arog Pharmaceuticals, Inc. 2017 - 2019
  • SARC 024: A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcomas awarded by Sarcoma Alliance for Research Through Collaboration 2015 - 2018
  • Dissecting Mechanisms of Metastasis Through Comparative Systems Genetics awarded by National Institutes of Health 2008 - 2013
• Publications & Artistic Works
• 

  Selected Publications

  • Book Sections

    • Larrier, N, Eward, WC, and Riedel, RF. "Bone Sarcomas." In Cancer Consult: Expertise for Clinical Practice, 687-695. June 20, 2014.  Full Text

  • Conference Papers

    • Chawla, S, Van Tine, BA, Pollack, S, Ganjoo, K, Elias, A, Riedel, RF, Attia, S, Choy, E, Okuno, S, Agulnik, M, von Mehren, M, Livingston, M, Keedy, V, Verschraegen, C, Philip, T, Bohac, C, Lu, H, Chen, M, and Maki, R. "A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival." September 2017.  Link to Item
    • Rav, EM, Riedel, RF, Rushing, CN, and Galanos, AN. "Healthcare utilization among cancer patients prior to hospice." : AMER SOC CLINICAL ONCOLOGY, October 9, 2016.  Link to Item
    • Whitley, MJ, Cardona, DM, Blazer, DG, Hwang, S, Greenup, RA, Mosca, PJ, Cahill, J, Mito, JK, Cuneo, KC, Larrier, N, O'Reilly, E, Spasojevic, I, Riedel, RF, Eward, WC, Griffith, LG, Bawendi, MG, Ferrer, J, Strasfeld, DB, Lee, WD, Brigman, B, and Kirsch, DG. "Abstract SY36-03: Intraoperative molecular imaging with protease-activated fluorescent imaging agents." August 1, 2015.  Full Text
    • Attia, S, Riedel, RF, Robinson, SI, Conry, RM, Sankhala, KK, Seon, BK, Alvarez, D, Adams, BJ, Theuer, CP, and Maki, RG. "A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS)." May 20, 2015.  Link to Item
    • Burgess, MA, Crowley, J, Reinke, DK, Riedel, RF, George, S, Movva, S, Van Tine, BA, Davis, LE, Schuetze, S, Hu, J, Attia, S, Priebat, DA, Reed, DR, D'Angelo, SP, Okuno, SH, Maki, RG, Patel, S, Baker, LH, and Tawbi, HA-H. "SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer. Chicago, IL. May 29, 2015 - June 2, 2015.: AMER SOC CLINICAL ONCOLOGY, May 20, 2015.  Link to Item
    • Whitley, MJ, Cardona, DM, Blazer, DG, Hwang, E, Greenup, RA, Mosca, PJ, Cahill, J, Mito, JK, Cuneo, KC, Larrier, N, O'Reilly, E, Spasojevic, I, Riedel, RF, Eward, WC, Griffith, LG, Bawendi, MG, Kirsch, DG, and Brigman, BE. "A Phase I Clinical Trial of LUM015: A Protease-activated Fluorescent Imaging Agent to Detect Cancer during Surgery." February 2015.  Link to Item
    • Whitley, MJ, Cardona, DM, Blazer, DG, Hwang, SE, Mosca, PJ, Cahill, J, Ferrer, JM, Strasfeld, DB, Mlto, JK, Cuneo, KC, Lanier, N, Williams, O, Spasojevic, I, Riedel, RF, Eward, W, Lee, WD, Griffith, LG, Bawendi, M, Kirsch, DG, and Brigman, BE. "A phase I study of the safety and activation of a cathepsin-activalable fluorescent cancer-specific probe LUM015." May 20, 2014.  Link to Item
    • LeBlanc, TW, Tulsky, JA, Abernethy, AP, Jones, CA, Galanos, AN, and Riedel, RF. "Oncologists' perceptions of rounding alongside palliative care physicians: Results of a post-intervention survey study." May 20, 2013.  Link to Item
    • Blay, J-Y, Chawla, SP, Ray-Coquard, I, Le Cesne, A, Staddon, AP, Milhem, MM, Penel, N, Riedel, RF, Nguyen, BB, Cranmer, LD, Reichardt, P, Bompas, E, Alcindor, T, Rushing, DA, Song, Y, Ebbinghaus, S, Haluska, FG, Dodion, PF, and Demetri, GD. "Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (>= 24 months) overall survival results." May 20, 2012.  Link to Item
    • Howard, LA, Bullock, KE, Bendell, JC, Uronis, HE, Vlahovic, G, Blobe, GC, Riedel, RF, Nixon, AB, Gockerman, JP, and Hurwitz, HI. "Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors." May 20, 2009.  Link to Item
    • Riedel, RF, Febbo, PG, and Crawford, L. "Identifying mechanisms of resistance in patients with locally advanced non-small cell lung cancer receiving dose-dense neoadjuvant/induction chemotherapy." January 2007.  Full Text  Link to Item

  • Journal Articles

    • Riedel, RF, Jones, RL, Italiano, A, Bohac, C, Thompson, JC, Mueller, K, Khan, Z, Pollack, SM, and Van Tine, BA. "Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review." Cancers 10, no. 11 (November 2018). (Review)  Full Text
    • Schwartz, AJ, Riedel, RF, LeBlanc, TW, Desai, D, Jenkins, C, Mahoney, E, Humphreys, J, and Hendrix, CC. "The experiences of older caregivers of cancer patients following hospital discharge." Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer (July 19, 2018).  Full Text
    • Vlahovic, G, Meadows, KL, Hatch, AJ, Jia, J, Nixon, AB, Uronis, HE, Morse, MA, Selim, MA, Crawford, J, Riedel, RF, Zafar, SY, Howard, LA, O'Neill, M, Meadows, JJ, Haley, ST, Arrowood, CC, Rushing, C, Pang, H, and Hurwitz, HI. "A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer." The Oncologist 23, no. 7 (July 2018): 782-790.  Full Text
    • Wisdom, AJ, Mowery, YM, Riedel, RF, and Kirsch, DG. "Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma." Cancer (May 3, 2018). (Review)  Full Text
    • von Mehren, M, Randall, RL, Benjamin, RS, Boles, S, Bui, MM, Ganjoo, KN, George, S, Gonzalez, RJ, Heslin, MJ, Kane, JM, Keedy, V, Kim, E, Koon, H, Mayerson, J, McCarter, M, McGarry, SV, Meyer, C, Morris, ZS, O'Donnell, RJ, Pappo, AS, Paz, IB, Petersen, IA, Pfeifer, JD, Riedel, RF, Ruo, B, Schuetze, S, Tap, WD, Wayne, JD, Bergman, MA, and Scavone, JL. "Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network 16, no. 5 (May 2018): 536-563.  Full Text
    • Plenker, D, Bertrand, M, de Langen, AJ, Riedel, R, Lorenz, C, Scheel, AH, Müller, J, Brägelmann, J, Daßler-Plenker, J, Kobe, C, Persigehl, T, Kluge, A, Wurdinger, T, Schellen, P, Hartmann, G, Zacherle, T, Menon, R, Thunnissen, E, Büttner, R, Griesinger, F, Wolf, J, Heukamp, L, Sos, ML, and Heuckmann, JM. "Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients." Clinical Cancer Research 24, no. 6 (March 15, 2018): 1337-1343.  Full Text
    • Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca, , and Cancer Genome Atlas Research Network, . "Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas." Cell 171, no. 4 (November 2017): 950-965.e28.  Full Text
    • Riedel, R, and Wolf, J. "[Personalized therapy of lung cancer - current standard and future challenges]." Deutsche medizinische Wochenschrift (1946) 142, no. 22 (November 2017): 1660-1668.  Full Text
    • Tawbi, HA, Burgess, M, Bolejack, V, Van Tine, BA, Schuetze, SM, Hu, J, D'Angelo, S, Attia, S, Riedel, RF, Priebat, DA, Movva, S, Davis, LE, Okuno, SH, Reed, DR, Crowley, J, Butterfield, LH, Salazar, R, Rodriguez-Canales, J, Lazar, AJ, Wistuba, II, Baker, LH, Maki, RG, Reinke, D, and Patel, S. "Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial." The Lancet. Oncology 18, no. 11 (November 2017): 1493-1501.  Full Text
    • Riedel, RF, Slusser, K, Power, S, Jones, CA, LeBlanc, TW, Kamal, AH, Desai, D, Allen, D, Yu, Y, Wolf, S, and Galanos, AN. "Improvements in Patient and Health System Outcomes Using an Integrated Oncology and Palliative Medicine Approach on a Solid Tumor Inpatient Service." Journal of Oncology Practice 13, no. 9 (September 2017): e738-e748.  Full Text
    • Tap, WD, Papai, Z, Van Tine, BA, Attia, S, Ganjoo, KN, Jones, RL, Schuetze, S, Reed, D, Chawla, SP, Riedel, RF, Krarup-Hansen, A, Toulmonde, M, Ray-Coquard, I, Hohenberger, P, Grignani, G, Cranmer, LD, Okuno, S, Agulnik, M, Read, W, Ryan, CW, Alcindor, T, Del Muro, XFG, Budd, GT, Tawbi, H, Pearce, T, Kroll, S, Reinke, DK, and Schöffski, P. "Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial." The Lancet. Oncology 18, no. 8 (August 2017): 1089-1103.  Full Text
    • Lopez-Pastorini, A, Riedel, R, Koryllos, A, Beckers, F, Ludwig, C, and Stoelben, E. "The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer." Lung cancer (Amsterdam, Netherlands) 109 (July 2017): 68-73.  Full Text
    • Riedel, RF, Meadows, KL, Lee, PH, Morse, MA, Uronis, HE, Blobe, GC, George, DJ, Crawford, J, Niedzwiecki, D, Rushing, CN, Arrowood, CC, and Hurwitz, HI. "Phase I study of pazopanib plus TH-302 in advanced solid tumors." Cancer Chemotherapy and Pharmacology 79, no. 3 (March 2017): 611-619.  Full Text
    • Wagner, AJ, Agulnik, M, Heinrich, MC, Mahadevan, D, Riedel, RF, von Mehren, M, Trent, J, Demetri, GD, Corless, CL, Yule, M, Lyons, JF, Oganesian, A, and Keer, H. "Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour." European journal of cancer (Oxford, England : 1990) 61 (July 2016): 94-101.  Full Text
    • von Mehren, M, Randall, RL, Benjamin, RS, Boles, S, Bui, MM, Conrad, EU, Ganjoo, KN, George, S, Gonzalez, RJ, Heslin, MJ, Kane, JM, Koon, H, Mayerson, J, McCarter, M, McGarry, SV, Meyer, C, O'Donnell, RJ, Pappo, AS, Paz, IB, Petersen, IA, Pfeifer, JD, Riedel, RF, Schuetze, S, Schupak, KD, Schwartz, HS, Tap, WD, Wayne, JD, Bergman, MA, and Scavone, J. "Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network : Jnccn 14, no. 6 (June 2016): 758-786.  Full Text
    • Hendrix, CC, Bailey, DE, Steinhauser, KE, Olsen, MK, Stechuchak, KM, Lowman, SG, Schwartz, AJ, Riedel, RF, Keefe, FJ, Porter, LS, and Tulsky, JA. "Effects of enhanced caregiver training program on cancer caregiver's self-efficacy, preparedness, and psychological well-being." Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer 24, no. 1 (January 2016): 327-336.  Full Text
    • Whitley, MJ, Cardona, DM, Lazarides, AL, Spasojevic, I, Ferrer, JM, Cahill, J, Lee, C-L, Snuderl, M, Blazer, DG, Hwang, ES, Greenup, RA, Mosca, PJ, Mito, JK, Cuneo, KC, Larrier, NA, O'Reilly, EK, Riedel, RF, Eward, WC, Strasfeld, DB, Fukumura, D, Jain, RK, Lee, WD, Griffith, LG, Bawendi, MG, Kirsch, DG, and Brigman, BE. "A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer." Science Translational Medicine 8, no. 320 (January 2016): 320ra4-null.  Full Text
    • Jiang, X, Anderson, HB, Guy, CD, Mosca, PJ, Riedel, RF, and Cardona, DM. "Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib." Case reports in oncological medicine 2015 (January 28, 2015): 317493-.  Full Text
    • Gwin, W, and Riedel, RF. "Chemotherapy in soft-tissue sarcoma: where do we go from here?." Oncology (Williston Park, N.Y.) 29, no. 1 (January 2015): 50-53.
    • Gwin, W, and Riedel, RF. "Chemotherapy in soft-tissue sarcoma: where do we go from here?." Oncology (Williston Park, N.Y.) 29, no. 1 (January 1, 2015).
    • Gwin, W, and Riedel, RF. "Chemotherapy in soft-tissue sarcoma: where do we go from here?." Oncology (Williston Park, N.Y.) 29, no. 1 (January 1, 2015).
    • Slusser, K, Power, S, Jones, CA, LeBlanc, TW, Kamal, A, Desai, D, Allen, D, and Galanos, AN. "Early palliative care on an inpatient oncology unit: Impact of a novel co-rounding partnership on patient and health system outcomes." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32, no. 31_suppl (November 2014): 3-.
    • Von Mehren, M, Randall, RL, Benjamin, RS, Boles, S, Bui, MM, Casper, ES, Conrad, EU, DeLaney, TF, Ganjoo, KN, George, S, Gonzalez, RJ, Heslin, MJ, Kane, JM, Mayerson, J, McGarry, SV, Meyer, C, O'Donnell, RJ, Pappo, AS, Paz, IB, Pfeifer, JD, Riedel, RF, Schuetze, S, Schupak, KD, Schwartz, HS, Van Tine, BA, Wayne, JD, Bergman, MA, and Sundar, H. "Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines." Jnccn Journal of the National Comprehensive Cancer Network 12, no. 6 (June 1, 2014): 853-862.  Full Text
    • von Mehren, M, Randall, RL, Benjamin, RS, Boles, S, Bui, MM, Casper, ES, Conrad, EU, DeLaney, TF, Ganjoo, KN, George, S, Gonzalez, RJ, Heslin, MJ, Kane, JM, Mayerson, J, McGarry, SV, Meyer, C, O'Donnell, RJ, Pappo, AS, Paz, IB, Pfeifer, JD, Riedel, RF, Schuetze, S, Schupak, KD, Schwartz, HS, Van Tine, BA, Wayne, JD, Bergman, MA, and Sundar, H. "Gastrointestinal stromal tumors, version 2.2014." Journal of the National Comprehensive Cancer Network : JNCCN 12, no. 6 (June 2014): 853-862.  Full Text
    • von Mehren, M, Randall, RL, Benjamin, RS, Boles, S, Bui, MM, Casper, ES, Conrad, EU, Delaney, TF, Ganjoo, KN, George, S, Gonzalez, RJ, Heslin, MJ, Kane, JM, Mayerson, J, McGarry, SV, Meyer, C, O'Donnell, RJ, Pappo, AS, Paz, IB, Pfeifer, JD, Riedel, RF, Schuetze, S, Schupak, KD, Schwartz, HS, Van Tine, BA, Wayne, JD, Bergman, MA, Sundar, H, and National Comprehensive Cancer Network, . "Soft tissue sarcoma, version 2.2014." Journal of the National Comprehensive Cancer Network : JNCCN 12, no. 4 (April 2014): 473-483.  Full Text
    • Meadows, KL, Lee, PH, Riedel, RF, Morse, MA, Uronis, HE, Blobe, GC, George, DJ, Crawford, J, and Hurwitz, HI. "Abstract C61: Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302." Molecular Cancer Therapeutics 12, no. 11_Supplement (November 1, 2013): C61-C61.  Full Text
    • Demetri, GD, Chawla, SP, Ray-Coquard, I, Le Cesne, A, Staddon, AP, Milhem, MM, Penel, N, Riedel, RF, Bui-Nguyen, B, Cranmer, LD, Reichardt, P, Bompas, E, Alcindor, T, Rushing, D, Song, Y, Lee, R-M, Ebbinghaus, S, Eid, JE, Loewy, JW, Haluska, FG, Dodion, PF, and Blay, J-Y. "Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 31, no. 19 (July 2013): 2485-2492.  Full Text
    • Larrier, NA, Kirsch, DG, Riedel, RF, Levinson, H, Eward, WC, and Brigman, BE. "Practical radiation oncology for extremity sarcomas." Surg Oncol Clin N Am 22, no. 3 (July 2013): 433-443. (Review)  Full Text  Link to Item
    • Cuneo, KC, Riedel, RF, Dodd, LG, Harpole, DH, and Kirsch, DG. "Pathologic complete response of a malignant peripheral nerve sheath tumor in the lung treated with neoadjuvant Ifosfamide and radiation therapy." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 30, no. 28 (October 2012): e291-e293.  Full Text
    • Vlahovic, G, Meadows, KL, Uronis, HE, Morse, MA, Blobe, GC, Riedel, RF, Zafar, SY, Alvarez-Secord, A, Gockerman, J, Starodub, AN, Ready, NE, Anderson, EL, Bendell, JC, and Hurwitz, HI. "A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors." Cancer Chemotherapy and Pharmacology 70, no. 1 (July 2012): 95-102.  Full Text
    • Riedel, RF, Porrello, A, Pontzer, E, Chenette, EJ, Hsu, DS, Balakumaran, B, Potti, A, Nevins, J, and Febbo, PC. "Retraction in part: A genomic approach to identify molecular pathways associated with chemotherapy resistance." Mol Cancer Ther 11, no. 5 (May 2012): 1214-1215.  Full Text  Link to Item
    • Riedel, RF. "Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches." Cancer 118, no. 6 (March 15, 2012): 1474-1485. (Review)  Full Text  Link to Item
    • Kim, S, Dodd, RD, Mito, JK, Ma, Y, Kim, Y, Riedel, RF, and Kirsch, DG. "Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma." Sarcoma 2012 (2012): 680708-.  Full Text  Link to Item
    • Mehren, MV, Benjamin, RS, Bui, MM, Casper, ES, III, EUC, DeLaney, TF, Ganjoo, KN, George, S, Gonzalez, R, Heslin, MJ, III, JMK, Mayerson, J, McGarry, SV, Meyer, C, O'Donnell, RJ, Paz, IB, Pfeifer, JD, Pollock, RE, Randall, RL, Riedel, RF, Schuetze, S, Schupak, KD, Schwartz, HS, Shankar, S, Tine, BAV, Wayne, J, Sundar, H, and McMillian, NR. "Soft tissue sarcoma, version 2.2012 featured updates to the NCCN guidelines." JNCCN Journal of the National Comprehensive Cancer Network 10, no. 8 (2012): 951-960.
    • Riedel, RF, Maki, RG, and Wagner, AJ. "Targeted therapy in sarcoma: should we be lumpers or splitters?." American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting (January 2012): 652-657.  Full Text
    • Riedel, RF. "Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?." Semin Oncol 38 Suppl 3 (October 2011): S30-S42. (Review)  Full Text  Link to Item
    • Smith, JL, and Riedel, RF. "Emerging therapeutic targets for soft tissue sarcoma." Curr Oncol Rep 13, no. 4 (August 2011): 350-358. (Review)  Full Text  Link to Item
    • Chawla, SP, Blay, J, Ray-Coquard, IL, Le Cesne, A, Staddon, AP, Milhem, MM, Penel, N, Riedel, RF, Bui Nguyen, B, Cranmer, LD, Reichardt, P, Bompas, E, Song, Y, Lee, R, Eid, JE, Loewy, J, Haluska, FG, Dodion, PF, and Demetri, GD. "Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT)." Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 10005-10005.  Full Text
    • Chawla, SP, Blay, J, Ray-Coquard, IL, Le Cesne, A, Staddon, AP, Milhem, MM, Penel, N, Riedel, RF, Bui Nguyen, B, Cranmer, LD, Reichardt, P, Bompas, E, Song, Y, Lee, R, Eid, JE, Loewy, J, Haluska, FG, Dodion, PF, and Demetri, GD. "Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 10005-.
    • Hsu, DS, Acharya, CR, Balakumaran, BS, Riedel, RF, Kim, MK, Stevenson, M, Tuchman, S, Mukherjee, S, Barry, W, Dressman, HK, and al, E. "Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer (Proceedings of the National Academy of Sciences of the United States of America (2009) 106, 13 (5312-5317) DOI: 10.1073/pnas.0900827106)." Proceedings of the National Academy of Sciences of the United States of America 108, no. 35 (2011): 14705--.  Full Text
    • Palta, M, Riedel, RF, Vredenburgh, JJ, Cummings, TJ, Green, S, Chang, Z, and Kirkpatrick, JP. "Primary meningeal rhabdomyosarcoma." Sarcoma 2011 (January 2011): 312802-null.  Full Text
    • Demetri, GD, Antonia, S, Benjamin, RS, Bui, MM, Casper, ES, Conrad, EU, DeLaney, TF, Ganjoo, KN, Heslin, MJ, Hutchinson, RJ, Kane, JM, Letson, GD, McGarry, SV, O'Donnell, RJ, Paz, IB, Pfeifer, JD, Pollock, RE, Randall, RL, Riedel, RF, Schupak, KD, Schwartz, HS, Thornton, K, von Mehren, M, Wayne, J, and National Comprehensive Cancer Network Soft Tissue Sarcoma Panel, . "Soft tissue sarcoma." Journal of the National Comprehensive Cancer Network : Jnccn 8, no. 6 (June 2010): 630-674.  Full Text
    • Demetri, GD, von Mehren, M, Antonescu, CR, DeMatteo, RP, Ganjoo, KN, Maki, RG, Pisters, PWT, Raut, CP, Riedel, RF, Schuetze, S, Sundar, HM, Trent, JC, and Wayne, JD. "NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors." Journal of the National Comprehensive Cancer Network : Jnccn 8 Suppl 2 (April 2010): S1-41.  Full Text
    • Mito, JK, Riedel, RF, Dodd, L, Lahat, G, Lazar, AJ, Dodd, RD, Stangenberg, L, Eward, WC, Hornicek, FJ, Yoon, SS, Brigman, BE, Jacks, T, Lev, D, Mukherjee, S, and Kirsch, DG. "Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. (Published online)" PLoS One 4, no. 11 (November 30, 2009): e8075-.  Full Text  Link to Item
    • Howard, LA, Bullock, KE, Bendell, JC, Uronis, HE, Vlahovic, G, Blobe, GC, Riedel, RF, Nixon, AB, Gockerman, JP, and Hurwitz, HI. "Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009): 3551-.
    • Riedel, RF, Larrier, N, Dodd, L, Kirsch, D, Martinez, S, and Brigman, BE. "The clinical management of chondrosarcoma." Curr Treat Options Oncol 10, no. 1-2 (April 2009): 94-106. (Review)  Full Text  Link to Item
    • Hsu, DS, Acharya, CR, Balakumaran, BS, Riedel, RF, Kim, MK, Stevenson, M, Tuchman, S, Mukherjee, S, Barry, W, Dressman, HK, Nevins, JR, Powers, S, Mu, D, and Potti, A. "Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer." Proc Natl Acad Sci U S A 106, no. 13 (March 31, 2009): 5312-5317.  Full Text  Link to Item
    • Ludwig, C, Riedel, R, Schnell, J, and Stoelben, E. "Inhalation with Tobramycin^® to improve healing of tracheobronchial reconstruction." European Journal of Cardio-thoracic Surgery 35, no. 5 (2009): 797-800.  Full Text
    • Riedel, RF, Porrello, A, Pontzer, E, Chenette, EJ, Hsu, DS, Balakumaran, B, Potti, A, Nevins, J, and Febbo, PG. "A genomic approach to identify molecular pathways associated with chemotherapy resistance." Mol Cancer Ther 7, no. 10 (October 2008): 3141-3149.  Full Text  Link to Item
    • Hsu, SD, Acharya, CR, Riedel, RF, Redman, RC, Garman, KS, Dressman, HK, Ginsburg, G, Powers, S, Mu, D, and Potti, A. "Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2-8, and PAX9, to predict prognosis and guide therapeutic strategies." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • Riedel, RF, Friedman, D, and Febbo, PG. "A genomic approach to identify therapeutic targets in histologic subtypes of soft tissue sarcoma." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • Hsu, SD, Acharya, CR, Riedel, RF, Redman, RC, Garman, KS, Dressman, HK, Ginsburg, G, Powers, S, Mu, D, and Potti, A. "Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2-8, and PAX9, to predict prognosis and guide therapeutic strategies." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26, no. 15_suppl (May 2008): 7511-.
    • Riedel, RF, Friedman, D, and Febbo, PG. "A genomic approach to identify therapeutic targets in histologic subtypes of soft tissue sarcoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26, no. 15_suppl (May 2008): 10577-.
    • Hsu, DS, Balakumaran, BS, Acharya, CR, Vlahovic, V, Walters, KS, Garman, K, Anders, C, Riedel, RF, Lancaster, J, Harpole, D, Dressman, HK, Nevins, JR, Febbo, PG, and Potti, A. "Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer." J Clin Oncol 25, no. 28 (October 1, 2007): 4350-4357.  Full Text  Link to Item
    • Riedel, RF, Andrews, C, Garst, J, Dunphy, F, Herndon, JE, Blackwell, S, Barbour, S, and Crawford, J. "A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer." J Thorac Oncol 2, no. 6 (June 2007): 520-525.  Full Text  Link to Item
    • Riedel, RF, Crawford, J, Dunphy, F, Herndon, JE, Garst, J, and Kelley, MJ. "Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer." Lung Cancer (Amsterdam, Netherlands) 54, no. 3 (December 2006): 431-432. (Letter)  Full Text
    • Riedel, RF, Wang, X, McCormack, M, Toloza, E, Montana, GS, Schreiber, G, and Kelley, MJ. "Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 1, no. 7 (September 2006): 692-696.  Full Text
    • Riedel, RF, and Burfeind, WR. "Thymoma: benign appearance, malignant potential." The Oncologist 11, no. 8 (September 2006): 887-894.  Full Text
    • Riedel, RF, and Febbo, PG. "Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer." Future Oncol 1, no. 4 (August 2005): 461-466. (Review)  Full Text  Link to Item
    • Riedel, RF, and Crawford, J. "Small-cell lung cancer: a review of clinical trials." Semin Thorac Cardiovasc Surg 15, no. 4 (October 2003): 448-456. (Review)  Link to Item
    • Luetteke, NC, Qiu, TH, Fenton, SE, Troyer, KL, Riedel, RF, Chang, A, and Lee, DC. "Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development." Development (Cambridge, England) 126, no. 12 (June 1999): 2739-2750.
    • Salomoni, P, Wasik, MA, Riedel, RF, Reiss, K, Choi, JK, Skorski, T, and Calabretta, B. "Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant." J Exp Med 187, no. 12 (June 15, 1998): 1995-2007.  Link to Item
    • Berkowitz, EA, Seroogy, KB, Schroeder, JA, Russell, WE, Evans, EP, Riedel, RF, Phillips, HK, Harrison, CA, Lee, DC, and Luetteke, NC. "Characterization of the mouse transforming growth factor alpha gene: its expression during eyelid development and in waved 1 tissues." Cell Growth Differ 7, no. 9 (September 1996): 1271-1282.  Link to Item
    • Meder, L, Schuldt, P, Thelen, M, Schmitt, A, Dietlein, F, Klein, S, Borchmann, S, Wennhold, K, Vlasic, I, Oberbeck, S, Riedel, R, Florin, A, Golfmann, K, Schlößer, HA, Odenthal, M, Büttner, R, Wolf, J, Hallek, M, Herling, M, von Bergwelt-Baildon, M, Reinhardt, HC, and Ullrich, RT. "Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer(Published online)." Cancer Research : canres.2176.2017-canres.2176.2017.  Full Text

  • Other Articles

    • Potti, A, Dressman, HK, Bild, A, Riedel, RF, Chan, G, Sayer, R, Cragun, J, Cottrill, H, Kelley, MJ, Petersen, R, Harpole, D, Marks, J, Berchuck, A, Ginsburg, GS, Febbo, P, Lancaster, J, and Nevins, JR. "Retraction: Genomic signatures to guide the use of chemotherapeutics." Nature Medicine 17, no. 1 (January 2011): 135-null.  Full Text
    • Potti, A, Dressman, HK, Bild, A, Riedel, RF, Chan, G, Sayer, R, Cragun, J, Cottrill, H, Kelley, MJ, Petersen, R, Harpole, D, Marks, J, Berchuck, A, Ginsburg, GS, Febbo, P, Lancaster, J, and Nevins, JR. "Erratum: Genomic signatures to guide the use of chemotherapeutics (Nature Medicine (2006) 12 (1294-1300))." Nature Medicine 17, no. 1 (January 1, 2011): 135-null.  Full Text
    • Hsu, DS, Balakumaran, BS, Acharya, CR, Vlahovic, V, Walters, KS, Garman, K, Anders, C, Riedel, RF, Lancaster, J, Harpole, D, and al, E. "Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer (Journal of Clinical Oncology (2007) 25, (4350-4357))." Journal of Clinical Oncology 28, no. 35 (2010): 5229--.  Full Text
    • Potti, A, Dressman, HK, Bild, A, Riedel, RF, Chan, G, Sayer, R, Cragun, J, Cottrill, H, Kelley, MJ, Petersen, R, Harpole, D, Marks, J, Berchuck, A, Ginsburg, GS, Febbo, P, Lancaster, J, and Nevins, JR. "Corrigendum: Genomic signatures to guide the use of chemotherapeutics (Nature Medicine (2006) 12, (1294-1300))." Nature Medicine 14, no. 8 (August 1, 2008): 889-null.  Full Text
    • Potti, A, Dressman, HK, Bild, A, Riedel, RF, Chan, G, Sayer, R, Cragun, J, Cottrill, H, Kelley, MJ, Petersen, R, Harpole, D, Marks, J, Berchuck, A, Ginsburg, GS, Febbo, P, Lancaster, J, and Nevins, JR. "Erratum: Genomic signatures to guide the use of chemotherapeutics (Nature (2006) 12, (1294-1300))." Nature Medicine 13, no. 11 (November 1, 2007): 1388-null.  Full Text
    • Potti, A, Dressman, HK, Bild, A, Riedel, RF, Chan, G, Sayer, R, Cragun, J, Cottrill, H, Kelley, MJ, Petersen, R, Harpole, D, Marks, J, Berchuck, A, Ginsburg, GS, Febbo, P, Lancaster, J, and Nevins, JR. "Genomic signatures to guide the use of chemotherapeutics." Nature Medicine 12, no. 11 (November 2006): 1294-1300.  Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.